JCR Pharmaceuticals Co., Ltd. has received the first approval worldwide, in Japan, for Izcargo (pabinafusp alfa), its novel therapy for mucopolysaccharidosis type II (MPS II, or Hunter syndrome).
The drug, formerly known as JR-141, was filed last September and is a recombinant fusion protein of an antibody against the human transferrin receptor and recombinant iduronate-2-sulfatase,